SG11201901995TA - Crystalline and salt forms of ppar agonist compounds - Google Patents
Crystalline and salt forms of ppar agonist compoundsInfo
- Publication number
- SG11201901995TA SG11201901995TA SG11201901995TA SG11201901995TA SG11201901995TA SG 11201901995T A SG11201901995T A SG 11201901995TA SG 11201901995T A SG11201901995T A SG 11201901995TA SG 11201901995T A SG11201901995T A SG 11201901995TA SG 11201901995T A SG11201901995T A SG 11201901995TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- english
- pct
- applicant
- salt forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901995TA true SG11201901995TA (en) | 2019-04-29 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901995TA SG11201901995TA (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (he) |
| EP (1) | EP3523283B1 (he) |
| JP (1) | JP7017563B2 (he) |
| KR (1) | KR20190057129A (he) |
| CN (1) | CN109843857B (he) |
| AU (1) | AU2017340763B2 (he) |
| CA (1) | CA3036587A1 (he) |
| CO (1) | CO2019003162A2 (he) |
| CY (1) | CY1124655T1 (he) |
| DK (1) | DK3523283T3 (he) |
| ES (1) | ES2887008T3 (he) |
| HR (1) | HRP20211341T1 (he) |
| HU (1) | HUE055678T2 (he) |
| IL (1) | IL265730B (he) |
| JO (1) | JOP20190039B1 (he) |
| LT (1) | LT3523283T (he) |
| MA (1) | MA46460A (he) |
| MX (1) | MX2019003945A (he) |
| MY (1) | MY202008A (he) |
| PH (1) | PH12019500727A1 (he) |
| PL (1) | PL3523283T3 (he) |
| PT (1) | PT3523283T (he) |
| RS (1) | RS62245B1 (he) |
| RU (1) | RU2759724C2 (he) |
| SG (1) | SG11201901995TA (he) |
| SI (1) | SI3523283T1 (he) |
| TW (1) | TWI769182B (he) |
| UA (1) | UA124770C2 (he) |
| WO (1) | WO2018067860A1 (he) |
| ZA (1) | ZA201901744B (he) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN108349904B (zh) * | 2015-10-07 | 2021-08-31 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| WO2018067860A1 (en) | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
| US11040039B2 (en) | 2017-10-10 | 2021-06-22 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
| EP3833660A4 (en) * | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
| WO2020085393A1 (ja) * | 2018-10-23 | 2020-04-30 | 国立研究開発法人科学技術振興機構 | ＰＰＡＲδ活性化剤 |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| JP2023526016A (ja) | 2020-05-13 | 2023-06-20 | アルデイラ セラピューティクス， インコーポレイテッド | 医薬製剤およびその使用 |
| WO2022256540A1 (en) | 2021-06-02 | 2022-12-08 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060241157A1 (en) | 2003-01-06 | 2006-10-26 | Conner Scott E | Heterocyclic ppar modulators |
| EP1671633A1 (en) | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
| WO2006084176A2 (en) | 2005-02-03 | 2006-08-10 | Irm Llc | Compounds and compositions as ppar modulators |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN108349904B (zh) * | 2015-10-07 | 2021-08-31 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| MX2018012538A (es) * | 2016-04-13 | 2019-02-25 | Mitobridge Inc | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos. |
| KR20190062502A (ko) | 2016-10-05 | 2019-06-05 | 미토브리지, 인크. | 급성 신장 손상을 치료하는 방법 |
| WO2018067860A1 (en) | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Crystalline and salt forms of ppar agonist compounds |
-
2017
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en active Application Filing
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Application Discontinuation
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 IL IL265730A patent/IL265730B/he unknown
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 MX MX2019003945A patent/MX2019003945A/es unknown
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-20 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201901925RA (en) | Methods of treating acute kidney injury | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201902974PA (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201809237RA (en) | Oxaborole esters and uses thereof | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases | |
| SG11201806622PA (en) | Egfl6 specific monoclonal antibodies and methods of their use |